These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 10513647)

  • 1. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.
    Tozzi V; Balestra P; Galgani S; Narciso P; Ferri F; Sebastiani G; D'Amato C; Affricano C; Pigorini F; Pau FM; De Felici A; Benedetto A
    AIDS; 1999 Oct; 13(14):1889-97. PubMed ID: 10513647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.
    Servais J; Schmit JC; Arendt V; Lambert C; Staub T; Robert I; Fontaine E; Plesséria JM; Burgy C; Kirpach P; Schneider F; Hemmer R
    HIV Clin Trials; 2000; 1(2):17-24. PubMed ID: 11590494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
    Powles T; Imami N; Nelson M; Gazzard BG; Bower M
    AIDS; 2002 Mar; 16(4):531-6. PubMed ID: 11872995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
    Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
    AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
    Bellman PC
    AIDS; 1998 Jul; 12(11):1333-40. PubMed ID: 9708413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.
    Li TS; Tubiana R; Katlama C; Calvez V; Ait Mohand H; Autran B
    Lancet; 1998 Jun; 351(9117):1682-6. PubMed ID: 9734884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.
    Cu-Uvin S; Caliendo AM; Reinert S; Chang A; Juliano-Remollino C; Flanigan TP; Mayer KH; Carpenter CC
    AIDS; 2000 Mar; 14(4):415-21. PubMed ID: 10770544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of prior nucleoside use on the two-year virological response to an initial protease inhibitor regimen in HIV-infected patients.
    Kazanjian P; Tashima K; Hollander T; Kaul D
    HIV Clin Trials; 2001; 2(3):213-8. PubMed ID: 11590530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
    Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
    AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.
    Andreoni M; Parisi SG; Sarmati L; Nicastri E; Ercoli L; Mancino G; Sotgiu G; Mannazzu M; Trevenzoli M; Tridente G; Concia E; Aceti A
    AIDS; 2000 Jan; 14(1):23-9. PubMed ID: 10714564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.
    Easterbrook PJ; Ives N; Waters A; Mullen J; O'Shea S; Peters B; Gazzard BG
    AIDS; 2002 Jul; 16(11):1521-7. PubMed ID: 12131190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.
    Cohen CJ; Hunt S; Sension M; Farthing C; Conant M; Jacobson S; Nadler J; Verbiest W; Hertogs K; Ames M; Rinehart AR; Graham NM;
    AIDS; 2002 Mar; 16(4):579-88. PubMed ID: 11873001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial.
    Kambugu A; Thompson J; Hakim J; Tumukunde D; van Oosterhout JJ; Mwebaze R; Hoppe A; Abach J; Kwobah C; Arenas-Pinto A; Walker SA; Paton NI;
    J Acquir Immune Defic Syndr; 2016 Apr; 71(5):506-13. PubMed ID: 26579985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.